Qinghe Xue

Qinghe Xue's work experience starts in 2009 as a Principal Scientist at AVEO Oncology, where they conducted translational research for a cancer metabolism drug discovery program. They then moved to Agios Pharmaceuticals in 2010 as an Associate Director, Biology, where they conducted translational research for another cancer metabolism drug discovery program. They supervised one PhD during their time at Agios. In 2011, they joined Forma Therapeutics as a Principal Scientist and Project Leader, leading multiple small molecule anti-cancer drug discovery programs and supervising PhD students. In 2016, they joined Proteostasis Therapeutics, Inc. (PTI) as a Senior Director, Biology, reporting to the Chief Scientific Officer. They established, led, and provided strategic directions for the small molecule drug discovery and development pipeline of the company, focusing on rare genetic diseases, oncology, and neurodegenerative diseases. In 2020, they became the Executive Director, Head of Biology at PTI before transitioning to their current role as Vice President, Head of Biology at Disc Medicine in January 2022.

Qinghe Xue's education history includes a Doctor of Philosophy (PhD) in Genetics/Developmental Biology from the University of Tennessee, Knoxville. Prior to that, they obtained a Bachelor of Science (B.Sc) in Biochemistry from Wuhan University. Additionally, Qinghe Xue was a Postdoctoral Fellow in Developmental Biology/Genome-wide Target Identification at the Massachusetts Institute of Technology.